Evidence map›Paper›PMID 40463543›Full record

ArticlemedRxiv : the preprint server for health sciences2025

VADEr: Vision Transformer-Inspired Framework for Polygenic Risk Reveals Underlying Genetic Heterogeneity in Prostate Cancer.

James V Talwar, Adam Klie, Meghana S Pagadala, Gil Pasternak, Brent Rose, Tyler M Seibert, Melissa Gymrek, Hannah Carter

Abstract readPreprint
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

James V TalwarDepartment of Medicine, Division of Medical Genetics, University of California San Diego, La Jolla, CA 92093, USA.ORCID 0000-0002-9520-1950
Adam KlieDepartment of Medicine, Division of Medical Genetics, University of California San Diego, La Jolla, CA 92093, USA.ORCID 0000-0002-7600-3086
Meghana S PagadalaDepartment of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10128, USA.ORCID 0000-0002-7591-6035
Gil PasternakDepartment of Computer Science and Engineering, University of California San Diego, La Jolla, CA 92093, USA.
Brent RoseDepartment of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla, CA 92093, USA.ORCID 0000-0002-3197-9552
Tyler M SeibertDepartment of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla, CA 92093, USA.ORCID 0000-0002-4089-7399
Melissa GymrekDepartment of Medicine, Division of Medical Genetics, University of California San Diego, La Jolla, CA 92093, USA.ORCID 0000-0002-6086-3903
Hannah CarterDepartment of Medicine, Division of Medical Genetics, University of California San Diego, La Jolla, CA 92093, USA.ORCID 0000-0002-1729-2463

Funding

GENETIC SUSCEPTIBILITY TO CANCER IN MULTIETHNIC COHORTSR01CA063464 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI HENDERSON, BRIAN E · 2001 to 2005
$23.2M
TR&D 3 - Network Guided Machine LearningP41GM103504 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI IDEKER, TREY · 2012 to 2024
$17.3M
Characterizing Genetic Susceptibility to Breast and Prostate Cancer; the BPC3U01CA098758 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI HENDERSON, BRIAN E · 2003 to 2010
$11.0M
Epidemiological and Clinical Translational Studies Post Genome-Wide AssociationU19CA148537 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI EASTON, DOUGLAS FREDERICK, EELES, ROSALIND · 2010 to 2014
$10.4M
MULTIETHNIC/MINORITY COHORT STUDY OF DIET AND CANCERR01CA054281 · NCI · UNIVERSITY OF HAWAII AT MANOA · PI KOLONEL, LAURENCE N. · 1993 to 2002
$4.5M
Comprehensive identification of germline-somatic interactionsR01CA269919 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Ludmil B Alexandrov, Hannah Kathryn Carter · 2022 to 2026
$2.2M
GENETIC SUSCEPTIBILITY TO CANCER IN MULTIETHNIC COHORTSU01CA063464 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI HENDERSON, BRIAN E · 1996 to 2000
$943k
NCI NIH HHS R01 CA054281NCI NIH HHS R01 CA063464NCI NIH HHS R01 CA269919NCI NIH HHS U01 CA063464NCI NIH HHS U01 CA098758NCI NIH HHS U19 CA148537NIGMS NIH HHS P41 GM103504
6 · The paper itself

Abstract

Polygenic risk scores (PRSs) serve as quantitative metrics of genetic liability for various conditions. Traditionally calculated as an effect size weighted genotype summation, this formulation assumes conditional feature independence and overlooks the potential for complex interactions among genetic variants. Transformers, a class of deep learning architectures known for capturing dependencies between features, have demonstrated remarkable predictive power across domains. In this work, we introduce VADEr, a Vision Transformer (ViT)-inspired architecture that combines techniques from both natural language processing and computer vision to capture properties exhibited by genetic data and model local and global interactions for genotype-to-phenotype prediction. Evaluating VADEr's performance in predicting prostate cancer (PCa) risk, we found that across a range of metrics, including accuracy, average precision, and Matthews correlation coefficient, VADEr outperformed all benchmark methods, demonstrating its effectiveness in the context of complex disease risk prediction. To illuminate identified drivers of disease risk by VADEr, we formulated DARTH scores, an attention-based attribution metric, to capture the personalized contribution of each genomic region. These scores revealed distinct genetic heterogeneity captured by VADEr, with drivers of predicted risk identified in key PCa risk regions including the

Indexed as

AttentionDARTH ScoresGenetic HeterogeneityProstate CancerPRSRelevanceTransformersVADEr

Identifiers

PMID40463543
PMCPMC12132116

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.